Jim Wilson startup Passage Bio plugs in CFO, CMO; Tillman Gerngross nabs a COO familiar with Covid-19 fight at Pfizer as Adagio files for IPO

Simona King

? Back in May, Passage Bio CFO Richard Morris and CMO Gary Romano left within days of each other, but this week the gene therapy player has found their replacements, along with a chief commercial officer. Simona King, a 19-year Bristol Myers Squibb vet in finance, becomes CFO on Aug. 23 after a quick stop in the same post at Tmunity Therapeutics and a year at Emergent BioSolutions. CMO Mark Forman gets started a week from today and was recently VP of translational medicine at Acadia Pharmaceuticals, preceded by 11 years at Merck. And Maria Törnsén, who got the ball rolling as CCO this week, had been Sarepta’s SVP, general manager, US.

Morris is currently CFO at Carisma Therapeutics after leaving Passage Bio, which had its FDA hold lifted for its infantile GM1 gangliosidosis drug PBGM01 to kick off…
Click here to view original post